Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FRAIL-IMMUNE
- 19 Aug 2019 Status changed from not yet recruiting to recruiting.
- 28 Jan 2019 Planned End Date changed from 15 Dec 2021 to 15 Mar 2022.
- 28 Jan 2019 Planned primary completion date changed from 15 Dec 2021 to 15 Mar 2022.